Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
101455808 | 10145580 | 8 | F | 20140226 | 20160928 | 20140501 | 20160930 | EXP | US-JNJFOC-20140418714 | JANSSEN | 13.11 | YR | C | F | Y | 41.10000 | KG | 20160930 | MD | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
101455808 | 10145580 | 1 | PS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | D | N | 103772 | LYOPHILIZED POWDER | ||||||||
101455808 | 10145580 | 2 | C | HUMIRA | ADALIMUMAB | 1 | Unknown | D | 0 | UNSPECIFIED | |||||||||
101455808 | 10145580 | 3 | C | IMURAN | AZATHIOPRINE | 1 | Unknown | D | 0 | UNSPECIFIED | |||||||||
101455808 | 10145580 | 4 | C | MULTIVITAMINS | VITAMINS | 1 | Unknown | D | 0 | UNSPECIFIED |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
101455808 | 10145580 | 1 | Inflammatory bowel disease |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
101455808 | 10145580 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
101455808 | 10145580 | Crohn's disease |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
101455808 | 10145580 | 1 | 20091210 | 0 | ||
101455808 | 10145580 | 2 | 20130401 | 20140408 | 0 |